Biolog "Middle East Licensing Agreement for COVID-19 Infection Prevention Agent"

[Asia Economy Reporter Hyunseok Yoo] Kosdaq-listed company Biolog Device announced on the 19th that its subsidiary BLD has completed the licensing agreement for Salbacion's coronavirus infection prevention nasal spray COVIXYL. The products included in this contract are COVIXYL-G, which kills 99.99% of bacteria, and COVIXYL-V, which can prevent coronavirus infection by 99.99% in advance.

The exclusive distribution rights covered by this contract include five Middle Eastern countries: Saudi Arabia, UAE, Iran, Egypt, and Turkey, encompassing major commercial areas and distribution channels connecting the Middle East and North Africa.

With this contract, BLD, which acquired the distribution rights for the five Middle Eastern countries, expressed confidence in the success of its business in the Middle East, as Biolog Device's CEO Hwang Hoon, who is an expert in the Middle East region and has extensive networks, leads the company.

Meanwhile, as the summer season progresses, there are concerns about a large-scale spread of coronavirus variants in the Middle East. The upcoming Muslim Eid al-Adha holiday, starting around the 20th, is expected to be a critical turning point.

In this regard, on the 14th, Al Jazeera reported that the WHO warned that "catastrophic consequences" are expected in the Middle East region.

This content was produced with the assistance of AI translation services.